← All trials
NCT06194799
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 23, 2024
- Primary completion
- Apr 30, 2029
- Completion date
- May 31, 2029
- First posted
- Jan 8, 2024
- Last posted
- Nov 4, 2024
- Enrollment
- 752
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Acadia PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.